



## Transparency notification of Vanguard Health Care Fund

**Participation on February 27, 2014 (pursuant to Article 6 of the law of May 2, 2007 on the disclosure of large shareholdings).**

**BRUSSELS (Belgium), March 6, 2014 – 18:30 (CET) – regulated information**

Pursuant to Article 14 of the law of May 2, 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received a transparency notification from Vanguard Health Care Fund (c/o The Vanguard Group, 455 Devon Park Drive, Wayne, PA 19087 USA).

Vanguard Health Care Fund has notified that, following the recent capital increase of UCB NV/SA of February 27, 2014 (see the press release of the same date for more information), it fell below the 5%-threshold.

On February 27, 2014, Vanguard Health Care Fund owned 9,345,949 UCB shares with voting rights, representing 4,96% of the total number of UCB voting rights (188,541,209).

Holders of voting rights	Notification of June 11, 2013	Notification of March 3, 2014	
	# of voting rights	# of voting rights	% of voting rights
Vanguard Health Care Fund	9,345,949	9,345,949	4.96 %
<b>TOTAL</b>	9,345,949	9,345,949	<b>4.96%</b>

An updated overview of the UCB SA/NV large shareholdings is included in the corporate governance charter of UCB SA/NV, which will be published on UCB SA/NV's website.

### For further information

- Antje Witte, Investor Relations UCB  
T +32.2.559.9414, antje.witte@ucb.com
- Alexandra Deschner, Investor Relations, UCB  
T +32 2 559 9683, alexandra.deschner@ucb.com
- France Nivelles, Global Communications UCB  
T +32.2.559.9178, france.nivelles@ucb.com
- Laurent Schots, Media Relations, UCB  
T +32.2.559.9264, laurent.schots@ucb.com

### About UCB

UCB, Brussels, Belgium ([www.ucb.com](http://www.ucb.com)) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 8700 people in approximately 40 countries, the company generated revenue of € 3.4 billion in 2013. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB\_news

### Forward looking statements

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable

terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.

There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.

Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.